TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* unintentional injury~Exclusion Criteria:~* intentional injury~* non-English speaking families~* children with cognitive impairment.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Psychological First Aid (Type: EXPERIMENTAL): Link for Injured Kids, a form of psychological first aid
- Trauma Education (Type: ACTIVE_COMPARATOR): Educational materials, So you've been in an accident provided to parents.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have an established diagnosis of radiographic axial spondyloarthritis (r-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.~* Participants have a history of back pain ≥3 months with age at onset \<45 years.~* Biologic naïve or have had prior treatment with 1 tumor necrosis factor (TNF) inhibitor.~* Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.~* Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.~Exclusion Criteria:~* Have total ankylosis of the spine.~* Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.~* Have an ongoing or serious infection within the last 12 weeks.~* Have a compromised immune system.~* Have any other serious and/or uncontrolled diseases.~* Have either a current diagnosis or a recent history of malignant disease.~* Have had major surgery within 8 weeks of baseline, or will require surgery during the study.~* Are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): Participants received Ixekizumab during the double-blind and extended treatment periods (i.e.,) starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during the follow-up period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo every four weeks (Q4W) by subcutaneous (SC) injection during the double-blind period. During the extension period, they received starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Piezo-surgery Technique and Intramuscular Dexamethasone Injection to Reduce Postoperative Pain After Impacted Mandibular Third Molar Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 15 to 30 years,~* Having mandibular impacted third molars,~Exclusion Criteria:~* Heavy smokers (≥20 cigarettes),~* Uncontrolled systemic conditions,~* Infection of the surgery site,~* Psychological problems,~* History of allergy to dexamethasone, amoxicillin, or acetaminophen.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Rotatory Instruments without Dexamethasone injection (Type: EXPERIMENTAL): Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy without Intramuscular Dexamethasone injection
- Rotatory Instruments with Dexamethasone injection (Type: EXPERIMENTAL): Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
- Piezosurgery technique without Dexamethasone injection (Type: EXPERIMENTAL): Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique without Intramuscular Dexamethasone injection
- Piezosurgery technique with Dexamethasone injection (Type: EXPERIMENTAL): Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique with 8 mg Intramuscular Dexamethasone injection 30 min before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient lumpectomy~* ASA I and II~* Age between 18-70~Exclusion:~* Pregnancy~* History of liver disease~* Unable to understand the informed consent~* Chronic pain with use of opioid in the last week~* Allergy to acetaminophen~Drop-out: surgeon or patient request

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IV acetaminophen (Type: ACTIVE_COMPARATOR): Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
- Placebo (Type: PLACEBO_COMPARATOR): Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Subject must have completed or be an eligible Baseline failure from the parent study (SP0982 \[NCT02408523\]). Note: Other subjects screened for SP0982 may be considered for roll-over to EP0012 if the investigator considers that the subject could benefit from treatment with open-label lacosamide (LCM) and based on prior discussion with and approval from the UCB Study Physician or representative~Exclusion Criteria:~* Subject is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM)~* Subject meets the withdrawal criteria for SP0982 or is experiencing an ongoing serious adverse event (SAE)~* Subject has an active suicidal ideation as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Since Last Visit version of the Columbia-Suicide Severity Rating Scale (C-SSRS)~* Subject has \>=2x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are \>ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35%). For all subjects who entered EP0012 directly with a Baseline result \>ULN for ALT, AST, ALP, or total bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the electronic Case Report form (eCRF). Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Start dose~SP0982 completers at V1:~* LCM 10 mg/kg/day for pediatric subjects weighing \<30 kg~* LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to \<50 kg~* LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~SP0982 Baseline failures at V1:~* LCM 2 mg/kg/day for pediatric subjects weighing \<50 kg~* LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~Oral solution (pediatric subjects \<50 kg):~* Minimum LCM dose: 4 mg/kg/day~* Maximum LCM dose: 12 mg/kg/day~Tablets (pediatric subjects ≥50kg):~* Minimum LCM dose: 200 mg/day~* Minimum LCM dose: 600 mg/day~Tablets (adult subjects):~* Minimum LCM dose: 200 mg/day~* Maximum LCM dose: 800 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective, unilateral, primary THA~* Age ≥ 18~* ASA 1-3~* BMI \> 18 and \< 40~* Negative urine HCG pregnancy test and use of anti-conception for women in the fertile age~* Give written informed consent to participate in the trial after having fully understood the contents of the protocol and restrictions~Exclusion Criteria:~* Patients who cannot cooperate with the trial~* Concomitant participation in another trial involving medication~* Patients who cannot understand or speak Danish~* Patients with allergy to medication used in the trial~* Patients with daily use of high dose opioid (\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids.~* Patients with daily use of systemic glucocorticoids (within 3 months before the trial)~* Contraindications against ibuprofen or paracetamol, for example previous ulcer, known heart failure, known liver failure, or known renal failure (eGRF \< 60 ml/kg/1,73m2), known thrombocytopenia (\< 100 x 109/l); or against treatment with glucocorticoids~* Dysregulated diabetes (investigator's judgement)~* Patients suffering from alcohol and/or drug abuse - based on the investigator's judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Paracetamol 1000 mg + Ibuprofen 400 mg administered orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus placebo (matching DXM) IV administered after induction of anaesthesia
- Group B (Type: EXPERIMENTAL): Paracetamol 1000 mg and placebo (matching ibuprofen) orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia
- Group C (Type: EXPERIMENTAL): Placebo (matching paracetamol) + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia
- Group D (Type: EXPERIMENTAL): Paracetamol 1000 mg + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Level Laser Light Therapy and Chronic Neck and Shoulder Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Location of pain is on the right and/or left side of the neck and/or shoulder and/or the back of the neck.~* Etiology of pain is osteoarthritis/Degenerative Joint Disorder (DJD); chronic muscle spasms or cervical and thoracic spine sprain strain, determined according to subject medical history, medication use history, previous records review, physical examination of the cervical spine and shoulder.~* Stage of injury is chronic, having prevailed for longer than 30 days.~* Degree of Pain self-rating of 50 or greater on the 0-100 Visual Analog Scale (VAS).~* 18-65 years.~Exclusion Criteria:~* Stage of injury is acute, having prevailed for less than 30 days.~* Known herniated disc injury.~* Any other disease or condition that may cause or contribute to the chronic pain condition.~* Presence of infection or open wound at the treatment areas.~* Use of steroids or narcotics.~* Use of over-the-counter (OTC) medication for the relief of pain within the 24-hour period prior to participating in the treatment phase of the study, or prescription medication for the relief of pain within the 48-hour period prior to participating in the treatment phase of the study.~* pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo laser (Type: PLACEBO_COMPARATOR): inactive laser light
- Erchonia PL2000 (Type: ACTIVE_COMPARATOR): The Erchonia PL2000 Laser emits 1 milliWatt (mW) of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STA-21 Topical Efficacy on Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A history of plaque psoriasis for a minimum of 2 years.~* In good general health, as evidenced by blood, renal function, and liver function tests conducted before commencing the study.~* Patients of childbearing age who agreed to continue using birth control for the duration of the study.~* Men or women between 20 and 80 years old.~Exclusion Criteria:~* Chronic plaque psoriasis involving \>40% of the body surface.~* Pustular or generalized erythrodermic psoriasis.~* Use of medications that might affect the psoriasis during the study~* Systemic therapy for psoriasis within 60 d of baseline.~* UV therapy within 21 d of baseline.~* Topical therapy within 14 d of baseline.~* Positive for HIV, hepatitis B, or hepatitis C.~* Clinically significant laboratory abnormality in blood, renal function, or liver function.~* Lactating, pregnant, or planning to become pregnant.~* Participation in another clinical trial in the last 30 d.~* Unwillingness to comply with the study protocol.~* Any other condition that in the opinion of the investigators could compromise the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Psoriasis therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Past prior SM interpreted as negative or benign \[Breast Imaging Reporting and Data System (BI-RADS) Category 1 or 2\]~* Past prior SM interpreted as heterogeneously dense or extremely dense~Exclusion Criteria:~* Subject is unable to understand and sign the consent form~* Subject is pregnant or lactating~* Subject is physically unable to sit upright and still for 40 minutes~* Subject has self-reported signs or symptoms of breast cancer (palpable mass, bloody nipple discharge, axillary mass, etc.)~* Subject has had needle biopsy within 3 months, or breast surgery within 1 year prior to the study~* Subject is currently taking tamoxifen, Evista (raloxifene), Zoladex or an aromatase inhibitor for adjuvant therapy or chemoprevention.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mammography and Molecular Breast Imaging (Type: EXPERIMENTAL): Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Volunteers able to understand and agree to participate in the study.~Exclusion Criteria:~* Have egg allergy~* Have past history of allergy to seasonal influenza vaccine~* Have received another inactivated vaccine within the prior 2 weeks or live vaccine in the past four weeks to his/her participation in the study~* Acute infectious disease during seven days prior vaccination~* Confirmed prior infection by pandemic influenza A (H1N1)~* Have participated in another clinical trial in the last 6 months~* Any other condition identified by the principal investigators which is considered not safe for enrollment of the volunteer.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Health adults (Type: None): None
- Health children (Type: None): None
- Pregnants (Type: None): None
- Elderly over 65 years old (Type: None): None
- HIV patients (Type: None): None
- Kidney transplant (Type: None): None
- Oncologic patients (Type: None): None
- Rheumatologic adult patients (Type: None): None
- Rheumatologic children patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 50 years of age diagnosed with wet age-related macular degeneration having indication of antiangiogenic therapy.~* Both genders.~* Subjects able to give informed consent.~Exclusion Criteria:~* Patients with contraindication to receive bevacizumab:~  * Hypersensitivity to the active ingredient or to some of the formula excipients.~ * Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies.~* Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment.~* Patients receiving previous systemic antiangiogenic therapy.~* Wet AMD in the healing period or disciform scar.~* Pregnant, breastfeeding or childbearing-aged women.~* Any person with choroidal neovascularization not associated to wet AMD.~* History of retinal or intraocular surgery in the affected eye in the last three months.~* Vitrectomy in the affected eye.~* Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied.~* Ocular inflammatory disease.~* Myopia exceeding -8 diopters.~* Extensive subfoveal subretinal hemorrhage \> 2 papillary diameter (PD).~* Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.~* History of stroke or myocardial infarction in the last 6 months.~* Patients with coagulopathies.~* Patients physically or mentally disabled to participate in such visual tests.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Lumiere®) (Type: EXPERIMENTAL): Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers who are able to fit in the WCD garment (26 to 56 inches measured circumferentially at the level of the xiphoid process).~* Included in this group are at least five healthy subjects with a self-reported history of heart failure.~* The subject must be 18 years of age or older on the day of screening, with at least 7 subjects 40 years of age or older on the day of screening.~Exclusion Criteria:~* Mental, visual, physical, literacy, and auditory limitations that prevent interaction with the WCD equipment.~* Any acute medical conditions that prevent the following maneuvers: lying on back, lying on the right and left side, standing, sitting, and/ or leaning forward when sitting.~* Any self-reported shortness of breath, fatigue, swelling of feet, ankles, or legs, and/or chest pain~* Employees or family members of the sponsor.~* Unable or unwilling to provide written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AUDICOR then LifeVest then AUDICOR (Type: OTHER): First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete